Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by apply...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 59; no. 2; p. 2003979
Main Authors Nakanishi, Tomoko, Cerani, Agustin, Forgetta, Vincenzo, Zhou, Sirui, Allen, Richard J., Leavy, Olivia C., Koido, Masaru, Assayag, Deborah, Jenkins, R. Gisli, Wain, Louise V., Yang, Ivana V., Lathrop, G. Mark, Wolters, Paul J., Schwartz, David A., Richards, J. Brent
Format Journal Article
LanguageEnglish
Published England European Respiratory Society 01.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside to the encoded gene ( -single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal. MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10 , respectively). Sensitivity analyses including multiple -SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of for IPF. An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF.
AbstractList After undertaking an efficient scan of 834 circulating proteins for their role in IPF risk using Mendelian randomisation, we found that individuals with genetically increased circulating FUT3 levels had lower risk of developing IPF https://bit.ly/3zCX8zf
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF.BACKGROUNDIdiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF.To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal.METHODSTo identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal.MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10-7 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10-5, respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10-6 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10-4 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF.RESULTSMR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10-7 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10-5, respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10-6 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10-4 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF.An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF.CONCLUSIONSAn efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF.
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside to the encoded gene ( -single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal. MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74-0.88; p=6.3×10 and OR 0.76, 95% CI 0.68-0.86; p=1.1×10 , respectively). Sensitivity analyses including multiple -SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78-0.91; p=9.8×10 and MR-Egger OR 0.69, 95% CI 0.50-0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77-0.92; p=1.4×10 and MR-Egger OR 0.59, 95% CI 0.38-0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of for IPF. An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF.
Author Schwartz, David A.
Richards, J. Brent
Jenkins, R. Gisli
Koido, Masaru
Zhou, Sirui
Wain, Louise V.
Nakanishi, Tomoko
Forgetta, Vincenzo
Lathrop, G. Mark
Cerani, Agustin
Leavy, Olivia C.
Wolters, Paul J.
Assayag, Deborah
Yang, Ivana V.
Allen, Richard J.
AuthorAffiliation 2 Centre for Clinical Epidemiology, Dept of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada
15 McGill Genome Centre and Dept of Human Genetics, McGill University, Montréal, QC, Canada
6 Dept of Health Sciences, University of Leicester, Leicester, UK
16 Dept of Medicine, School of Medicine, University of California, San Francisco, CA, USA
17 Dept of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA
1 Dept of Human Genetics, McGill University, Montréal, QC, Canada
10 National Heart and Lung Institute, Imperial College London, London, UK
7 Dept of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
19 Dept of Twin Research, King's College London, London, UK
9 Translational Research in Respiratory Diseases, Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, QC, Canada
13 Center for Genes, Environment and Health and Dept of Medicine, National Jewish Health, Denver,
AuthorAffiliation_xml – name: 14 Dept of Medicine, School of Medicine, University of Colorado Denver, Aurora, CO, USA
– name: 3 Kyoto–McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
– name: 5 Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC, Canada
– name: 7 Dept of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
– name: 10 National Heart and Lung Institute, Imperial College London, London, UK
– name: 11 Dept of Interstitial Lung Disease, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK
– name: 19 Dept of Twin Research, King's College London, London, UK
– name: 8 Dept of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada
– name: 1 Dept of Human Genetics, McGill University, Montréal, QC, Canada
– name: 12 National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK
– name: 17 Dept of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA
– name: 4 Japan Society for the Promotion of Science, Tokyo, Japan
– name: 16 Dept of Medicine, School of Medicine, University of California, San Francisco, CA, USA
– name: 6 Dept of Health Sciences, University of Leicester, Leicester, UK
– name: 18 Division of Endocrinology, Dept of Medicine, Jewish General Hospital, McGill University, Montréal, QC, Canada
– name: 9 Translational Research in Respiratory Diseases, Research Institute of the McGill University Health Centre (RI-MUHC), Montréal, QC, Canada
– name: 13 Center for Genes, Environment and Health and Dept of Medicine, National Jewish Health, Denver, CO, USA
– name: 15 McGill Genome Centre and Dept of Human Genetics, McGill University, Montréal, QC, Canada
– name: 2 Centre for Clinical Epidemiology, Dept of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada
Author_xml – sequence: 1
  givenname: Tomoko
  orcidid: 0000-0001-9510-5646
  surname: Nakanishi
  fullname: Nakanishi, Tomoko
– sequence: 2
  givenname: Agustin
  orcidid: 0000-0002-9633-7796
  surname: Cerani
  fullname: Cerani, Agustin
– sequence: 3
  givenname: Vincenzo
  orcidid: 0000-0002-6061-4720
  surname: Forgetta
  fullname: Forgetta, Vincenzo
– sequence: 4
  givenname: Sirui
  orcidid: 0000-0003-4963-0815
  surname: Zhou
  fullname: Zhou, Sirui
– sequence: 5
  givenname: Richard J.
  orcidid: 0000-0002-8450-3056
  surname: Allen
  fullname: Allen, Richard J.
– sequence: 6
  givenname: Olivia C.
  orcidid: 0000-0002-1503-5535
  surname: Leavy
  fullname: Leavy, Olivia C.
– sequence: 7
  givenname: Masaru
  orcidid: 0000-0002-0348-0666
  surname: Koido
  fullname: Koido, Masaru
– sequence: 8
  givenname: Deborah
  orcidid: 0000-0002-2497-9984
  surname: Assayag
  fullname: Assayag, Deborah
– sequence: 9
  givenname: R. Gisli
  orcidid: 0000-0002-7929-2119
  surname: Jenkins
  fullname: Jenkins, R. Gisli
– sequence: 10
  givenname: Louise V.
  orcidid: 0000-0003-4951-1867
  surname: Wain
  fullname: Wain, Louise V.
– sequence: 11
  givenname: Ivana V.
  orcidid: 0000-0002-1018-489X
  surname: Yang
  fullname: Yang, Ivana V.
– sequence: 12
  givenname: G. Mark
  orcidid: 0000-0002-2660-7105
  surname: Lathrop
  fullname: Lathrop, G. Mark
– sequence: 13
  givenname: Paul J.
  orcidid: 0000-0002-3108-6164
  surname: Wolters
  fullname: Wolters, Paul J.
– sequence: 14
  givenname: David A.
  orcidid: 0000-0001-6743-8443
  surname: Schwartz
  fullname: Schwartz, David A.
– sequence: 15
  givenname: J. Brent
  orcidid: 0000-0002-3746-9086
  surname: Richards
  fullname: Richards, J. Brent
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34172473$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1vFCEYJk2N3W79BU0MRy9T-ZoZ8GBiGltNanppz-RdYFqUhRWYJnvvD5dtu0Y9eAHy8nzA8xyjw5iiQ-iUkjNKJX9PuVKcEH5GuBpVxwgjB2ixm3a78SFaEEV4RxUfjtBxKd8JoYPg9DU64oKOTIx8gR4vXXTVGwhhi3002UFxFhufzRyg-niHL25vOA7uwYW2gi24JpydnU3DZV9-4DRhb33aQL33Bm_msE4R8hZPfpVT8eUDBvzNReuCh4gzRJvWvjTxFHGps92eoFcThOLevOxLdHvx-eb8S3d1ffn1_NNVZwTpawdyYnayo4UVlWDYKKx0ExPtAEQYYod-NU5WjsPApOJ2UIxwwaUUwwQEgC_Rx2fdzbxaO2tcrBmC3mS_bu_VCbz--yb6e32XHrSUTVD1TeDdi0BOP2dXqm4fMS4EiC7NRbNe9L0aafNdord_ev022UffAOoZYFpIJbtJG1-fQmnWPmhK9K5mva9ZP9WsdzU3Lv-Hu5f_H-sX19ytAg
CitedBy_id crossref_primary_10_1136_thorax_2024_221398
crossref_primary_10_1093_postmj_qgae140
crossref_primary_10_1186_s12890_024_03289_y
crossref_primary_10_3390_jcm12113713
crossref_primary_10_1016_j_ocarto_2024_100540
crossref_primary_10_1371_journal_pone_0300423
crossref_primary_10_1111_resp_14511
crossref_primary_10_1111_cts_13442
crossref_primary_10_1164_rccm_202401_0238SO
crossref_primary_10_3389_fimmu_2023_1168023
crossref_primary_10_1007_s00432_023_04612_6
crossref_primary_10_1038_s41598_025_85338_y
Cites_doi 10.1002/ijc.32033
10.1136/bmj.k601
10.1093/bioinformatics/btz469
10.1093/oxfordjournals.molbev.a004138
10.1002/pmic.201900278
10.1056/NEJMoa1402584
10.1371/journal.pmed.0050093
10.1016/j.ajhg.2016.10.003
10.1164/rccm.201810-1891OC
10.1002/ijc.23907
10.1183/13993003.03545-2020
10.1136/jmedgenet-2014-102438
10.1056/NEJMoa1402582
10.1136/gutjnl-2012-303434
10.1126/sciadv.aba1983
10.1016/j.bjhh.2016.07.005
10.1038/nrcardio.2017.156
10.1056/NEJMoa1809944
10.1038/s41467-018-07768-9
10.7554/eLife.34408
10.1093/ije/dyx034
10.1002/gepi.21758
10.1093/hmg/ddx071
10.1093/bioinformatics/btq419
10.1016/S2213-2600(17)30430-7
10.1136/thoraxjnl-2018-212446
10.1183/13993003.00120-2015
10.1186/s12931-019-1190-z
10.1056/NEJMc1014719
10.1164/rccm.2009-040GL
10.1038/s41569-020-00493-1
10.1378/chest.96.1.68
10.1038/s41586-018-0175-2
10.1093/aje/kwy204
10.1371/journal.pgen.1007081
10.3390/ijms21072269
10.1038/s41467-018-05512-x
10.1016/S0140-6736(21)00676-0
10.1093/bioinformatics/btw018
10.1164/rccm.201509-1863OC
10.1093/ije/dyx038
10.1038/s41576-019-0127-1
10.1126/science.aaq1327
10.1126/sciadv.aba1972
10.1161/CIRCGENETICS.116.001396
10.1056/NEJMoa1013660
10.1371/journal.ppat.1005555
10.1093/bioinformatics/btw373
10.1371/journal.pgen.1004383
10.1378/chest.11-0284
10.1183/09031936.00077309
10.1016/S2213-2600(18)30185-1
10.1371/journal.pone.0092111
10.1136/thx.2010.151555
10.1016/S0140-6736(17)30866-8
10.1136/thoraxjnl-2012-202943
10.1164/rccm.201505-0862OC
10.1164/rccm.201905-1017OC
10.1002/sim.6835
10.1016/j.bbagen.2014.05.003
ContentType Journal Article
Copyright Copyright ©The authors 2022.
Copyright ©The authors 2022. 2022
Copyright_xml – notice: Copyright ©The authors 2022.
– notice: Copyright ©The authors 2022. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1183/13993003.03979-2020
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Genetically increased circulating FUT3 level and risk of IPF
EISSN 1399-3003
ExternalDocumentID PMC8828995
34172473
10_1183_13993003_03979_2020
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R38 HL143511
– fundername: Department of Health
– fundername: Wellcome Trust
– fundername: Cancer Research UK
– fundername: NHLBI NIH HHS
  grantid: UH3 HL123442
– fundername: NHLBI NIH HHS
  grantid: UH3 HL151865
– fundername: NHLBI NIH HHS
  grantid: UG3 HL151865
– fundername: NIEHS NIH HHS
  grantid: R25 ES025476
– fundername: NHLBI NIH HHS
  grantid: T32 HL007085
– fundername: NHLBI NIH HHS
  grantid: UH2 HL123442
– fundername: ;
– fundername: ;
  grantid: 365825; 409511
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AADJU
AAFWJ
AAYXX
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CITATION
COF
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7X8
5PM
ID FETCH-LOGICAL-c405t-a8f2dfd7dab18ac274d8ef24274a04c0d65b7fd87662893d69203438846fa0aa3
ISSN 0903-1936
1399-3003
IngestDate Thu Aug 21 13:59:16 EDT 2025
Fri Jul 11 10:55:13 EDT 2025
Wed Feb 19 02:24:05 EST 2025
Thu Apr 24 22:50:55 EDT 2025
Tue Jul 01 05:42:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright ©The authors 2022.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-a8f2dfd7dab18ac274d8ef24274a04c0d65b7fd87662893d69203438846fa0aa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2660-7105
0000-0002-8450-3056
0000-0001-6743-8443
0000-0002-9633-7796
0000-0002-3108-6164
0000-0001-9510-5646
0000-0003-4963-0815
0000-0002-1018-489X
0000-0002-6061-4720
0000-0002-0348-0666
0000-0002-7929-2119
0000-0003-4951-1867
0000-0002-1503-5535
0000-0002-2497-9984
0000-0002-3746-9086
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8828995
PMID 34172473
PQID 2545597120
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8828995
proquest_miscellaneous_2545597120
pubmed_primary_34172473
crossref_citationtrail_10_1183_13993003_03979_2020
crossref_primary_10_1183_13993003_03979_2020
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-01
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2022
Publisher European Respiratory Society
Publisher_xml – name: European Respiratory Society
References 2024102102334771000_59.2.2003979.16
2024102102334771000_59.2.2003979.15
2024102102334771000_59.2.2003979.59
2024102102334771000_59.2.2003979.58
Allen (2024102102334771000_59.2.2003979.11) 2020; 201
2024102102334771000_59.2.2003979.13
Kamat (2024102102334771000_59.2.2003979.26) 2019; 35
Yao (2024102102334771000_59.2.2003979.32) 2018; 9
2024102102334771000_59.2.2003979.19
Fanidi (2024102102334771000_59.2.2003979.44) 2019; 145
2024102102334771000_59.2.2003979.18
2024102102334771000_59.2.2003979.17
2024102102334771000_59.2.2003979.52
2024102102334771000_59.2.2003979.51
2024102102334771000_59.2.2003979.50
2024102102334771000_59.2.2003979.12
2024102102334771000_59.2.2003979.56
2024102102334771000_59.2.2003979.55
2024102102334771000_59.2.2003979.10
2024102102334771000_59.2.2003979.54
2024102102334771000_59.2.2003979.53
Davey Smith (2024102102334771000_59.2.2003979.14) 2019; 7
2024102102334771000_59.2.2003979.27
2024102102334771000_59.2.2003979.25
2024102102334771000_59.2.2003979.24
2024102102334771000_59.2.2003979.29
2024102102334771000_59.2.2003979.28
Maher (2024102102334771000_59.2.2003979.57) 2017; 5
Nongmaithem (2024102102334771000_59.2.2003979.31) 2017; 26
2024102102334771000_59.2.2003979.60
2024102102334771000_59.2.2003979.23
2024102102334771000_59.2.2003979.22
2024102102334771000_59.2.2003979.21
2024102102334771000_59.2.2003979.38
2024102102334771000_59.2.2003979.37
Landray (2024102102334771000_59.2.2003979.42) 2021; 397
2024102102334771000_59.2.2003979.36
2024102102334771000_59.2.2003979.35
2024102102334771000_59.2.2003979.39
Neighbors (2024102102334771000_59.2.2003979.9) 2018; 6
Dupuy (2024102102334771000_59.2.2003979.49) 2002; 19
Giambartolomei (2024102102334771000_59.2.2003979.20) 2014; 10
Moore (2024102102334771000_59.2.2003979.47) 2019; 200
Raffield (2024102102334771000_59.2.2003979.61) 2020; 20
2024102102334771000_59.2.2003979.30
2024102102334771000_59.2.2003979.34
2024102102334771000_59.2.2003979.33
2024102102334771000_59.2.2003979.1
2024102102334771000_59.2.2003979.48
2024102102334771000_59.2.2003979.46
2024102102334771000_59.2.2003979.5
2024102102334771000_59.2.2003979.4
2024102102334771000_59.2.2003979.3
2024102102334771000_59.2.2003979.2
2024102102334771000_59.2.2003979.8
2024102102334771000_59.2.2003979.7
2024102102334771000_59.2.2003979.6
2024102102334771000_59.2.2003979.41
2024102102334771000_59.2.2003979.40
2024102102334771000_59.2.2003979.45
2024102102334771000_59.2.2003979.43
References_xml – volume: 145
  start-page: 1499
  year: 2019
  ident: 2024102102334771000_59.2.2003979.44
  article-title: Is high vitamin B12 status a cause of lung cancer?
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32033
– ident: 2024102102334771000_59.2.2003979.17
  doi: 10.1136/bmj.k601
– volume: 35
  start-page: 4851
  year: 2019
  ident: 2024102102334771000_59.2.2003979.26
  article-title: PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btz469
– volume: 19
  start-page: 815
  year: 2002
  ident: 2024102102334771000_59.2.2003979.49
  article-title: α1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently
  publication-title: Mol Biol Evol
  doi: 10.1093/oxfordjournals.molbev.a004138
– volume: 20
  start-page: 1900278
  year: 2020
  ident: 2024102102334771000_59.2.2003979.61
  article-title: Comparison of proteomic assessment methods in multiple cohort studies
  publication-title: Proteomics
  doi: 10.1002/pmic.201900278
– ident: 2024102102334771000_59.2.2003979.3
  doi: 10.1056/NEJMoa1402584
– ident: 2024102102334771000_59.2.2003979.6
  doi: 10.1371/journal.pmed.0050093
– ident: 2024102102334771000_59.2.2003979.21
  doi: 10.1016/j.ajhg.2016.10.003
– volume: 200
  start-page: 199
  year: 2019
  ident: 2024102102334771000_59.2.2003979.47
  article-title: Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201810-1891OC
– ident: 2024102102334771000_59.2.2003979.58
  doi: 10.1002/ijc.23907
– ident: 2024102102334771000_59.2.2003979.43
  doi: 10.1183/13993003.03545-2020
– ident: 2024102102334771000_59.2.2003979.45
  doi: 10.1136/jmedgenet-2014-102438
– ident: 2024102102334771000_59.2.2003979.4
  doi: 10.1056/NEJMoa1402582
– ident: 2024102102334771000_59.2.2003979.33
  doi: 10.1136/gutjnl-2012-303434
– ident: 2024102102334771000_59.2.2003979.29
  doi: 10.1126/sciadv.aba1983
– ident: 2024102102334771000_59.2.2003979.53
  doi: 10.1016/j.bjhh.2016.07.005
– ident: 2024102102334771000_59.2.2003979.40
  doi: 10.1038/nrcardio.2017.156
– ident: 2024102102334771000_59.2.2003979.39
  doi: 10.1056/NEJMoa1809944
– ident: 2024102102334771000_59.2.2003979.56
  doi: 10.1038/s41467-018-07768-9
– ident: 2024102102334771000_59.2.2003979.18
  doi: 10.7554/eLife.34408
– ident: 2024102102334771000_59.2.2003979.23
  doi: 10.1093/ije/dyx034
– ident: 2024102102334771000_59.2.2003979.19
  doi: 10.1002/gepi.21758
– volume: 26
  start-page: 2551
  year: 2017
  ident: 2024102102334771000_59.2.2003979.31
  article-title: GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddx071
– ident: 2024102102334771000_59.2.2003979.22
  doi: 10.1093/bioinformatics/btq419
– volume: 5
  start-page: 946
  year: 2017
  ident: 2024102102334771000_59.2.2003979.57
  article-title: An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(17)30430-7
– ident: 2024102102334771000_59.2.2003979.5
  doi: 10.1136/thoraxjnl-2018-212446
– ident: 2024102102334771000_59.2.2003979.52
  doi: 10.1183/13993003.00120-2015
– ident: 2024102102334771000_59.2.2003979.35
  doi: 10.1186/s12931-019-1190-z
– ident: 2024102102334771000_59.2.2003979.50
  doi: 10.1056/NEJMc1014719
– ident: 2024102102334771000_59.2.2003979.59
  doi: 10.1164/rccm.2009-040GL
– ident: 2024102102334771000_59.2.2003979.41
  doi: 10.1038/s41569-020-00493-1
– ident: 2024102102334771000_59.2.2003979.8
  doi: 10.1378/chest.96.1.68
– ident: 2024102102334771000_59.2.2003979.12
  doi: 10.1038/s41586-018-0175-2
– ident: 2024102102334771000_59.2.2003979.10
  doi: 10.1093/aje/kwy204
– ident: 2024102102334771000_59.2.2003979.34
  doi: 10.1371/journal.pgen.1007081
– ident: 2024102102334771000_59.2.2003979.36
  doi: 10.3390/ijms21072269
– volume: 9
  start-page: 3268
  year: 2018
  ident: 2024102102334771000_59.2.2003979.32
  article-title: Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-05512-x
– volume: 397
  start-page: 1637
  year: 2021
  ident: 2024102102334771000_59.2.2003979.42
  article-title: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00676-0
– ident: 2024102102334771000_59.2.2003979.30
  doi: 10.1093/bioinformatics/btw018
– ident: 2024102102334771000_59.2.2003979.46
  doi: 10.1164/rccm.201509-1863OC
– ident: 2024102102334771000_59.2.2003979.16
  doi: 10.1093/ije/dyx038
– ident: 2024102102334771000_59.2.2003979.15
  doi: 10.1038/s41576-019-0127-1
– ident: 2024102102334771000_59.2.2003979.13
  doi: 10.1126/science.aaq1327
– ident: 2024102102334771000_59.2.2003979.28
  doi: 10.1126/sciadv.aba1972
– ident: 2024102102334771000_59.2.2003979.38
  doi: 10.1161/CIRCGENETICS.116.001396
– ident: 2024102102334771000_59.2.2003979.55
  doi: 10.1056/NEJMoa1013660
– ident: 2024102102334771000_59.2.2003979.54
  doi: 10.1371/journal.ppat.1005555
– ident: 2024102102334771000_59.2.2003979.25
  doi: 10.1093/bioinformatics/btw373
– volume: 10
  start-page: e100438
  year: 2014
  ident: 2024102102334771000_59.2.2003979.20
  article-title: Bayesian test for colocalisation between pairs of genetic association studies using summary statistics
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1004383
– ident: 2024102102334771000_59.2.2003979.60
  doi: 10.1378/chest.11-0284
– ident: 2024102102334771000_59.2.2003979.2
  doi: 10.1183/09031936.00077309
– volume: 6
  start-page: 615
  year: 2018
  ident: 2024102102334771000_59.2.2003979.9
  article-title: Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30185-1
– ident: 2024102102334771000_59.2.2003979.48
  doi: 10.1371/journal.pone.0092111
– ident: 2024102102334771000_59.2.2003979.37
  doi: 10.1136/thx.2010.151555
– ident: 2024102102334771000_59.2.2003979.1
  doi: 10.1016/S0140-6736(17)30866-8
– ident: 2024102102334771000_59.2.2003979.27
  doi: 10.1136/thoraxjnl-2012-202943
– ident: 2024102102334771000_59.2.2003979.7
  doi: 10.1164/rccm.201505-0862OC
– volume: 7
  start-page: 27857v
  year: 2019
  ident: 2024102102334771000_59.2.2003979.14
  article-title: STROBE-MR: guidelines for strengthening the reporting of Mendelian randomisation studies
  publication-title: Peer J Preprints
– volume: 201
  start-page: 564
  year: 2020
  ident: 2024102102334771000_59.2.2003979.11
  article-title: Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201905-1017OC
– ident: 2024102102334771000_59.2.2003979.24
  doi: 10.1002/sim.6835
– ident: 2024102102334771000_59.2.2003979.51
  doi: 10.1016/j.bbagen.2014.05.003
SSID ssj0016431
Score 2.4466915
Snippet Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal...
After undertaking an efficient scan of 834 circulating proteins for their role in IPF risk using Mendelian randomisation, we found that individuals with...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2003979
SubjectTerms Fucosyltransferases - genetics
Genome-Wide Association Study
Humans
Idiopathic Pulmonary Fibrosis - genetics
Mendelian Randomization Analysis - methods
Original s
Polymorphism, Single Nucleotide
Title Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study
URI https://www.ncbi.nlm.nih.gov/pubmed/34172473
https://www.proquest.com/docview/2545597120
https://pubmed.ncbi.nlm.nih.gov/PMC8828995
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKkKZdEN-ULxmJW8nIh9M43CZENYGGhNSiiUvk2s4W1iZVmlx25s6_zHtO4qTbQMAlqpLYSfr7JX7v-fn3CHkdhO5SCaGdFMY7h8kY3jnf5Y4KQrmMdSA9Izx_8nl6vGAfT8PT0ejnIGuprpaH8vLGdSX_gyrsA1xxlew_IGs7hR3wG_CFLSAM27_CGDWjTSx6hav30P7bgv0os1Kaolz52WS2mAeTFSYGYX0IZeQcSlRr1X1WeaaywhQmlpNNvYKbx0S6FNzoYpttm8XQJxgoNwERGNpUsW5zgAbitN971tkAfzmYxh8-D8aexYXIMfxl-FKsi4vCzobosqkzNTk6w1Jjlr0zE71vrN2v8Lg6v7SNvp0XtQnkZmWdDSMZ4AS7NitEN19fsJacwHWD4ee5FQzPei_5-lefo_oEtsbGhy7OVQJRzCq7asCDzdoQAQbuyGdNBZUrYtvdoVvktg9-B5bE-PSln5YC881rpavgmm9vuOIB2e_62LV0rrkvV7NwB2bN_C650_oj9Kgh1z0y0vl9sn_SZlw8ID8GHKOWY3TAMYoco4Zj1HCMVgVtOUaRY7RIac8xajlGO469o4JahtEdhlHDsIdkMfswf3_stJU7HAkOQOUInvoqVZESS48L6UdMcZ2CNRgx4TLpqmm4jFIFI_EUHP5ATWPfDVjAwRhOhStE8Ijs5UWunxAaCpFqJUIRM87SSMUpn3pce4zxWEimx8Tv_uVEtrL2WF1llRj3lgdJh1JiUEoQpTF5YxttGlWXP5_-qoMvgefHKTWR66LeJj44IOCSe3jO4wZO22HHgzGJdoC2J6Cy--6RPDs3Cu_cxEHCp7_t8xk56N-g52SvKmv9AqzjavnSMPYXSUW-VA
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetically+increased+circulating+FUT3+level+leads+to+reduced+risk+of+idiopathic+pulmonary+fibrosis%3A+a+Mendelian+randomisation+study&rft.jtitle=The+European+respiratory+journal&rft.au=Nakanishi%2C+Tomoko&rft.au=Cerani%2C+Agustin&rft.au=Forgetta%2C+Vincenzo&rft.au=Zhou%2C+Sirui&rft.date=2022-02-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=2&rft_id=info:doi/10.1183%2F13993003.03979-2020&rft_id=info%3Apmid%2F34172473&rft.externalDocID=34172473
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon